- Conditions
- Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
- Interventions
- Belimumab, Placebo
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Interstitial Pneumonias
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Durham, North Carolina
- Conditions
- Sarcoidosis, Sarcoidosis, Pulmonary
- Interventions
- Observational Study
- Other
- Lead sponsor
- National Jewish Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Systemic Sclerosis (SSc), Scleroderma
- Interventions
- Tibulizumab, Placebo
- Biological · Other
- Lead sponsor
- Zura Bio Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- La Jolla, California • Plantation, Florida • Iowa City, Iowa + 3 more
- Conditions
- Telomere Biology Disorders, Dyskeratosis Congenita, Revesz Syndrome, Hoyeraal Hreidarsson Syndrome, Telomere Biology Disorders With Bone Marrow Failure, Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Pulmonary Fibrosis, Familial (Telomere Biology Disorder)
- Interventions
- deoxycytidine, deoxythymidine
- Drug
- Lead sponsor
- Suneet Agarwal
- Other
- Eligibility
- 1 Year to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer, Radiation Pneumonitis
- Interventions
- Enalapril, placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Ann Arbor, Michigan • Milwaukee, Wisconsin
- Conditions
- Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
- Interventions
- Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • New York, New York • Durham, North Carolina + 1 more
- Conditions
- Systemic Sclerosis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Arlington, Texas
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34,960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Ridgefield, Connecticut
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- MNKD-201(Nintedanib DPI), Placebo
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 9
- States / cities
- Fresno, California • Palm Springs, California • Doral, Florida + 5 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Interstitial Lung Disease
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 400 participants
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BBT-877, Single dose, Placebo group, BBT-877, Multiple doses
- Drug
- Lead sponsor
- Bridge Biotherapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
- Interventions
- Rituximab, Placebo
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
- Interventions
- Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Ivosidenib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Lung Diseases, Interstitial, Pulmonary Fibrosis
- Interventions
- CT-V, Metabolites
- Device · Other
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Belumosudil, BSC
- Drug · Other
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 7 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Vismodegib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 14
- States / cities
- La Jolla, California • Orlando, Florida • Elk Grove, Illinois + 11 more
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Diseases, Langerhans-Cell Histiocytosis, Hematologic Diseases
- Interventions
- Stem Cell Transplant, Myeloablative conditioning regimen
- Procedure · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Transplant, Kidney Transplantation
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • La Jolla, California • Chicago, Illinois + 2 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression
- Interventions
- Palliative Care, Standard of Care
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Interstitial Lung Disease
- Interventions
- Pulmonary rehabilitation
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Concord, California • Daly City, California • New Haven, Connecticut + 2 more
- Conditions
- COVID-19
- Interventions
- APX-115, Placebo
- Drug
- Lead sponsor
- Aptabio Therapeutics, Inc.
- Individual
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more